KEYLYNK-009: A phase 2/3, open-label, randomized study of pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with first-line pembrolizumab plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

被引：1

作者：

Rugo, Hope ^{[1
]}

Llombart-Cussac, Antonio ^{[2
]}

Andre, Fabrice ^{[3
]}

Robson, Mark E. ^{[4
]}

Saji, Shigehira ^{[5
]}

Harbeck, Nadia ^{[6
]}

Schmid, Peter ^{[7
]}

Cescon, David ^{[8
]}

Ahn, Jin Seok ^{[9
]}

Nanda, Rita ^{[10
]}

Fan, Li ^{[11
]}

Mejia, Jaime Alberto ^{[11
]}

Karantza, Vassiliki ^{[11
]}

Bardia, Aditya ^{[12
]}

机构：

[1] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA

[2] Hosp Arnau Vilanova, Valencia, Spain

[3] Gustave Roussy, Fac Med Paris Sud XI, Villejuif, France

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Fukushima Med Univ, Fukushima, Japan

[6] Ludwig Maximilian Univ Munich LMU, Breast Ctr, Munich, Germany

[7] Barts Canc Inst, London, England

[8] Univ Toronto, Toronto, ON, Canada

[9] Sungkyunkwan Univ, Coll Med, Seoul, South Korea

[10] Univ Chicago, Chicago, IL 60637 USA

[11] Merck & Co Inc, Kenilworth, NJ USA

[12] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA

来源：

CANCER RESEARCH | 2021年 / 81卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS20-OT-30-01

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OT-30-01

引用

页数：1

共 50 条

[1] Pembrolizumab plus Olaparib vs Pembrolizumab plus Chemotherapy After Induction With Pembrolizumab plus Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study
Rugo, Hope
Robson, Mark
Im, Seock-Ah
Dalenc, Florence
Ruiz, Eduardo Yanez
Im, Young-Hyuck
Kulyk, Sergii
Dudnichenko, Oleksandr
Llinas-Quintero, Nestor
Saji, Shigehira
Miyoshi, Yasuo
Harbeck, Nadia
Fan, Li
Mejia, Jaime
Karantza, Vassiliki
Cescon, David
CANCER RESEARCH, 2024, 84 (09)
[2] A phase II/III, open-label, randomized trial of pembrolizumab plus olaparib vs. pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009
Rugo, H. S.
Llombart Cussac, A.
Andre, F.
Robson, M.
Saji, S.
Harbeck, N.
Schmid, P.
Cescon, D. W.
Ahn, J. Seok
Nanda, R.
Fan, L.
Mejia, J.
Karantza, V.
Bardia, A.
ANNALS OF ONCOLOGY, 2020, 31 : S392 - S392
[3] KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).
Rugo, Hope S.
Llombart-Cussac, Antonio
Andre, Fabrice
Robson, Mark E.
Saji, Shigehira
Harbeck, Nadia
Schmid, Peter
Cescon, David W.
Ahn, Jin Seok
Nanda, Rita
Bardia, Aditya
Fan, Li
Mejia, Jaime Alberto
Karantza, Vassiliki
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[4] KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib (ola) vs pembro plus chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Saji, S.
Cussac, A. Llombart
Andre, F.
Robson, M. E.
Harbeck, N.
Schmid, P.
Cescon, D. W.
Ahn, J. S.
Nanda, R.
Fan, L.
Mejia, J. A.
Karantza, V.
Bardia, A.
Rugo, H. S.
ANNALS OF ONCOLOGY, 2020, 31 : S1268 - S1268
[5] Additional Efficacy Endpoints From the Phase 3 KEYNOTE-355 Study of Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as First-Line Therapy for Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 11 - 12
[6] Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer
Haiderali, Amin
Huang, Min
Pan, Wilbur
Akers, Katherine G.
Maciel, Dylan
Frederickson, Andrew M.
FUTURE ONCOLOGY, 2024, 20 (22) : 1587 - 1600
[7] Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
Cortes, Javier
Cescon, David W.
Rugo, Hope S.
Nowecki, Zbigniew
Im, Seock-Ah
Yusof, Mastura Md
Gallardo, Carlos
Lipatov, Oleg
Barrios, Carlos Henrique
Holgado, Esther
Iwata, Hiroji
Masuda, Norikazu
Otero, Marco Torregroza
Gokmen, Erhan
Loi, Sherene
Guo, Zifang
Zhao, Jing
Aktan, Gursel
Karantza, Vassiliki
Schmidi, Peter
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Safety evaluation from the KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy in patients with previously untreated, locally recurrent inoperable or metastatic triple-negative breast cancer
Rugo, Hope
Schmid, Peter
Nowecki, Zbigniew
Cescon, David
Im, Seock-Ah
Yusof, Mastura
Gallardo, Carlos
Iwata, Hiroji
Barrios, Carlos
Loi, Sherene
Zhou, Xuan
Zhang, Xiaoli
Pan, Wilbur
Karantza, Vassiliki
Cortes, Javier
CANCER RESEARCH, 2024, 84 (09)
[9] Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer
Cortes, Javier
Cescon, David W.
Rugo, Hope S.
Nowecki, Zbigniew
Im, Seock-Ah
Yusof, Mastura Md
Gallardo, Carlos
Lipatov, Oleg
Barrios, Carlos Henrique
Perez-Garcia, Jose
Iwata, Hiroji
Masuda, Norikazu
Otero, Marco Torregroza
Gokmen, Erhan
Loi, Sherene
Guo, Zifang
Zhou, Xuan
Karantza, Vassiliki
Pan, Wilbur
Schmid, Peter
CANCER RESEARCH, 2022, 82 (04)
[10] KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC)
Cortes, Javier
Guo, Zifang
Karantza, Vassiliki
Aktan, Gursel
CANCER RESEARCH, 2017, 77

← 1 2 3 4 5 →